Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia

Carlo Marani, Marino Clavio, Raffaella Grasso, Nicoletta Colombo, Fabio Guolo, Annalisa Kunkl, Filippo Ballerini, Livia Giannoni, Chiara Ghiggi, Giuseppina Fugazza, Jean Louis Ravetti, Marco Gobbi, Maurizio Miglino

Research output: Contribution to journalArticle

Abstract

Fifty uniformly treated adult AML patients were analyzed with respect to pre-treatment and post-induction risk factors. Forty-two patients achieving complete hematological remission were assessed for minimal residual disease (MRD) by WT1 gene expression; 34 by flow-cytometry (flow-MRD). Patients who were flow-MRD negative had a better 3-year disease-free (DFS; 79.5% vs. 27.3%; p= .032) compared with patients who were still positive after induction. Interestingly, DFS of flow-MRD positive patients was not related to the amount of flow-detected clone population (≥ or

Original languageEnglish
Pages (from-to)1606-1611
Number of pages6
JournalLeukemia Research
Volume37
Issue number12
DOIs
Publication statusPublished - Dec 2013

Keywords

  • Acute myeloid leukemia
  • Early response assessment
  • Flow-cytometry
  • Minimal residual disease
  • Prognosis
  • Wilms' tumor gene

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this